-

Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Category: IR

Contacts

DexCom, Inc.:
Sean Christensen
Senior Vice President – Finance and Investor Relations
investor-relations@dexcom.com
(858) 200-0200

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Versions
English

Contacts

DexCom, Inc.:
Sean Christensen
Senior Vice President – Finance and Investor Relations
investor-relations@dexcom.com
(858) 200-0200

More News From DexCom, Inc.

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D...

Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. “We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom’s president and CEO. “Today’s a...

Dexcom to Host Investor Day on May 14, 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will be available on the Dexcom Investor Relations website at investors.dexcom.c...
Back to Newsroom